VX-264
Phase 2Small molecule
Vertex PharmaceuticalsVX-264 is one of 34 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Mounjaro
Eli LillyApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ozempic
Novo NordiskPhase 3
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Diamox
TevaPhase 2
Kerendia
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VX-264. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company